In terms of adverse effects within CDK4/6 inhibitors, pooled analysis demonstrated that abemaciclib was significantly better than others regarding neutropenia of grade ≥3 (OR, 0.035; 95% CrI, 0.0058–0.15) (Supplementary Figure 7). The gene discussed is CDK4; the disease is neutropenia.